Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
European Institute of Oncology
University of Chile
Pliant Therapeutics, Inc.
The University of Queensland
University of Kansas Medical Center
Damae Medical
RemeGen Co., Ltd.
Herlev Hospital
Centre Hospitalier Universitaire de Nice
JS InnoPharm, LLC
University Hospital Rijeka
Bispebjerg Hospital
M.D. Anderson Cancer Center
Universidade do Porto
Institute of Oncology Ljubljana
Assistance Publique - Hôpitaux de Paris
Peter MacCallum Cancer Centre, Australia
University of Aleppo
Delcath Systems Inc.
Leiden University Medical Center
Provectus Pharmaceuticals
Helsinki University Central Hospital
The Netherlands Cancer Institute
Andalusian Network for Design and Translation of Advanced Therapies
OncoResponse, Inc.
Universitair Ziekenhuis Brussel
Massachusetts General Hospital
University of Utah
Karolinska University Hospital
Philogen S.p.A.
Keio University
Massachusetts General Hospital
Centre Hospitalier Universitaire Vaudois
Biocad
Peking Union Medical College Hospital
Bio-Thera Solutions
Melanoma Institute Australia
Center for Biomedical Research, Inc.
The Christie NHS Foundation Trust
Region Stockholm
Biocad
Kineta Inc.
BGI, China
Fujian Cancer Hospital
NovalGen Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
PrimeVax Immuno-Oncology Inc.
The Netherlands Cancer Institute
Fudan University
Peking University Cancer Hospital & Institute